黑料社

Dementia Education Program Newsletter

Hughlings Jackson Lecture 2025: The Basal Ganglia and the Motivation to Act

Thursday, November 13, 2025 16:00to17:00

Established in 1935, the Hughlings Jackson Lecture is The Neuro鈥檚 premier scientific lecture. It honours the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the...

Hands-on workshop: Learn how to make your own science outreach and protocol videos

Monday, September 29, 2025 02:00to04:30

Atelier "Atelier pratique : Apprenez 脿 cr茅er vos propres vid茅os de vulgarisation scientifique et de protocole" Cet atelier sera pr茅sent茅 en anglais./neuroCategory:聽MNI

Neuro Staff Appreciation Day 2025

Thursday, September 4, 2025 11:00to14:00

Staff Appreciation Day is exclusively for Neuro staff, faculty, nurses, students, and trainees. ID required to enter./neuroCategory:聽MNI Staff

AI analysis of healthcare records reveals key factors in autism diagnosis

Published: 26 March 2025

Scientists argue the criteria we use for diagnosing autism may need revision...

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Published: 14 March 2025

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation...

Project to create AI model for ALS receives G茅nome Qu茅bec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Alan Evans receives Order of Canada

Published: 30 June 2025

Career of breakthroughs in neuroimaging recognized with one of the nation鈥檚 highest honours ...

Latest Alzheimer鈥檚 drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...

Pages

Back to top